- Home
- EVG vs CLLS Comparison
EVG vs CLLS Comparison
Compare EVG & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVG
- CLLS
- Stock Information
- Founded
- EVG 2005
- CLLS 1999
- Country
- EVG United States
- CLLS France
- Employees
- EVG N/A
- CLLS N/A
- Industry
- EVG Investment Managers
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- EVG Finance
- CLLS Health Care
- Exchange
- EVG Nasdaq
- CLLS Nasdaq
- Market Cap
- EVG 149.9M
- CLLS 148.1M
- IPO Year
- EVG N/A
- CLLS 2007
- Fundamental
- Price
- EVG $10.68
- CLLS $1.45
- Analyst Decision
- EVG
- CLLS Buy
- Analyst Count
- EVG 0
- CLLS 3
- Target Price
- EVG N/A
- CLLS $7.00
- AVG Volume (30 Days)
- EVG 49.4K
- CLLS 120.5K
- Earning Date
- EVG 01-01-0001
- CLLS 05-27-2025
- Dividend Yield
- EVG 8.68%
- CLLS N/A
- EPS Growth
- EVG N/A
- CLLS N/A
- EPS
- EVG N/A
- CLLS N/A
- Revenue
- EVG N/A
- CLLS $49,217,000.00
- Revenue This Year
- EVG N/A
- CLLS $1.26
- Revenue Next Year
- EVG N/A
- CLLS N/A
- P/E Ratio
- EVG N/A
- CLLS N/A
- Revenue Growth
- EVG N/A
- CLLS 435.38
- 52 Week Low
- EVG $9.13
- CLLS $1.10
- 52 Week High
- EVG $10.86
- CLLS $3.38
- Technical
- Relative Strength Index (RSI)
- EVG 46.23
- CLLS 60.38
- Support Level
- EVG $10.46
- CLLS $1.40
- Resistance Level
- EVG $10.76
- CLLS $1.56
- Average True Range (ATR)
- EVG 0.23
- CLLS 0.09
- MACD
- EVG -0.00
- CLLS 0.03
- Stochastic Oscillator
- EVG 51.81
- CLLS 76.09
About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.